Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP298419.RA5TGYVwC0JewhZ5A2300yt5UpCBZhwCZnSnKQi5FPDG4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP298419.RA5TGYVwC0JewhZ5A2300yt5UpCBZhwCZnSnKQi5FPDG4130_assertion type Assertion NP298419.RA5TGYVwC0JewhZ5A2300yt5UpCBZhwCZnSnKQi5FPDG4130_head.
- NP298419.RA5TGYVwC0JewhZ5A2300yt5UpCBZhwCZnSnKQi5FPDG4130_assertion description "[Molecular therapeutic approaches, for example, those directed against the fusion protein BCR-ABL with ABL-tyrosine kinase inhibitor, are on the way to creating a new avenue for the treatment of ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP298419.RA5TGYVwC0JewhZ5A2300yt5UpCBZhwCZnSnKQi5FPDG4130_provenance.
- NP298419.RA5TGYVwC0JewhZ5A2300yt5UpCBZhwCZnSnKQi5FPDG4130_assertion evidence source_evidence_literature NP298419.RA5TGYVwC0JewhZ5A2300yt5UpCBZhwCZnSnKQi5FPDG4130_provenance.
- NP298419.RA5TGYVwC0JewhZ5A2300yt5UpCBZhwCZnSnKQi5FPDG4130_assertion SIO_000772 11049022 NP298419.RA5TGYVwC0JewhZ5A2300yt5UpCBZhwCZnSnKQi5FPDG4130_provenance.
- NP298419.RA5TGYVwC0JewhZ5A2300yt5UpCBZhwCZnSnKQi5FPDG4130_assertion wasDerivedFrom befree-2016 NP298419.RA5TGYVwC0JewhZ5A2300yt5UpCBZhwCZnSnKQi5FPDG4130_provenance.
- NP298419.RA5TGYVwC0JewhZ5A2300yt5UpCBZhwCZnSnKQi5FPDG4130_assertion wasGeneratedBy ECO_0000203 NP298419.RA5TGYVwC0JewhZ5A2300yt5UpCBZhwCZnSnKQi5FPDG4130_provenance.